Navigation Links
BDSI Announces Positive Key Secondary Efficacy Endpoint Results for,Bema Fentanyl

MORRISVILLE, N.C.--(BUSINESS WIRE)--May 14, 2007 - BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced additional statistically significant results with BEMA Fentanyl in cancer patients with breakthrough pain in its Phase III efficacy clinical trial for the product.

Results were based on the company's continuing analysis of the secondary efficacy endpoints from the study. A key secondary endpoint was the SPID 15 (Summary of Pain Intensity Difference at 15 minutes), a measure of the speed of onset of the medication. The study data indicate that the SPID 15 was significantly higher on BEMA(TM) Fentanyl than with placebo.

On April 25, 2007, BDSI announced statistically significant results of its primary efficacy endpoint for the BEMA(TM) Fentanyl Phase III trial, SPID 30 (Summary of Pain Intensity Difference at 30 minutes). BEMA(TM) Fentanyl consists of a small, dissolvable polymer disc, formulated with the opioid narcotic fentanyl, for application to the buccal (inner lining of cheek) membranes. Upon administration, BEMA(TM) Fentanyl is designed to deliver a rapid, reliable dose of drug across the mucous membranes.

In addition to the SPID 15 endpoint, the company also reported that the overall global analysis of the treatment, which represents each patient's overall satisfaction with the product, was also found to be statistically superior to the placebo.

Dr. Andrew Finn, BDSI's Executive Vice President of Product Development, stated: "We are very pleased with the outcome of the results from our current secondary endpoint analyses from our Phase III efficacy study which, as previously announced, we plan to present along with other efficacy and safety data at an upcoming scientific forum to be determined. We are particularly pleased to see that the onset of analgesia with BEMA(TM) Fentanyl is rapid, since a quick onset of action is one of the anticipated features of delivering fe
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:7/22/2014)... Calif. , July 22, 2014  Based ... imaging (MRI) market, Frost & Sullivan recognizes Siemens ... Product Leadership. Siemens Healthcare,s FREEZEit solution, which employs ... need for robust and motion-insensitive imaging. The solution,s ... the evolution of body MRI imaging in the ...
(Date:7/22/2014)... 2014 Sanofi Pasteur, the vaccines division of Sanofi ... that the first lots of Fluzone ® (Influenza Vaccine) ... by the U.S. Food and Drug Administration (FDA) for distribution. ... first of at least 65 million doses of seasonal influenza ... U.S. health care providers and pharmacies in August. ...
(Date:7/22/2014)... 2014 Galmed Pharmaceuticals Ltd. (Nasdaq: ... the development and commercialization of a once-daily, oral therapy ... announced today that the U.S. Food and Drug Administration, ... IND, application.  Such clearance will permit Galmed to conduct ... the United States for the treatment ...
Breaking Medicine Technology:Frost & Sullivan Recognizes Siemens Healthcare with the Product Leadership Award for Innovative Techniques in Abdominal Imaging 2Frost & Sullivan Recognizes Siemens Healthcare with the Product Leadership Award for Innovative Techniques in Abdominal Imaging 3Frost & Sullivan Recognizes Siemens Healthcare with the Product Leadership Award for Innovative Techniques in Abdominal Imaging 4Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 2Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 3Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 4Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 5Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 6Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 7Galmed Announces FDA Clearance of IND of Armachol for the Treatment of Fatty Liver Disorders 2Galmed Announces FDA Clearance of IND of Armachol for the Treatment of Fatty Liver Disorders 3Galmed Announces FDA Clearance of IND of Armachol for the Treatment of Fatty Liver Disorders 4
... HealthCare, Inc., (Pink Sheets: SFSH ) announced ... program to launch SinoFresh products in international markets. This ... market in the United States.  To facilitate sales in ... Company will immediately begin to implement the following: ...
... Calif., Feb. 28, 2011 At the ARPA-E Energy ... CDXS ) will announce significant progress towards ... emissions from coal-fired power plants.  The program is supported ... plants are major emitters of carbon dioxide, a significant ...
Cached Medicine Technology:SinoFresh Healthcare, Inc. Takes Groundbreaking Products to Europe 2Codexis Announces Carbon Capture Progress at ARPA-E Summit 2Codexis Announces Carbon Capture Progress at ARPA-E Summit 3
(Date:7/22/2014)... (PRWEB) July 22, 2014 United Benefit ... organization, announces that Les McPhearson, an insurance veteran with ... CEO effective immediately and be based in the company's ... "I am delighted that Les chose to accept this ... qualified to address the many challenges facing UBA and ...
(Date:7/22/2014)... 2014) The American Society of Hematology (ASH) ... of California Los Angeles with the 2014 E. ... homeostasis, including the discovery of the iron-regulatory hormone hepcidin ... award, named after the Nobel Prize Laureate and past ... achievements in hematology that have represented a paradigm shift ...
(Date:7/22/2014)... comes to heart disease, Dr. Ross Feldman says women are ... disease was a men,s-only disease, however, data has shown that ... heart disease and are less likely to be adequately diagnosed ... week in the British Journal of Clinical Pharmacology ... women and helps to identify which women are more prone ...
(Date:7/22/2014)... mechanisms with cancer, according to a new report by ... , published in PLOS ONE on July ... very same inhibitors of apoptosis, or cell destruction, in ... diseases. Henry Kaminski, M.D. , chair of the ... and Health Sciences (SMHS), as well as colleagues from ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 The ... http://www.risperdallawsuitcenter.com/ ) in the Philadelphia Court ... deny punitive damages in cases alleging the medication ... Bernstein Liebhard LLP reports. In an Order dated ... a plaintiffs’ request to certify the matter for ...
Breaking Medicine News(10 mins):Health News:Industry Leader Les McPhearson Joins United Benefit Advisors as New Chief Executive Officer 2Health News:Industry Leader Les McPhearson Joins United Benefit Advisors as New Chief Executive Officer 3Health News:Industry Leader Les McPhearson Joins United Benefit Advisors as New Chief Executive Officer 4Health News:Industry Leader Les McPhearson Joins United Benefit Advisors as New Chief Executive Officer 5Health News:Tomas Ganz, M.D., Ph.D., to present 2014 ASH E. Donnall Thomas Lecture 2Health News:Tomas Ganz, M.D., Ph.D., to present 2014 ASH E. Donnall Thomas Lecture 3Health News:Gene variant identified as a heart disease risk factor for women 2Health News:New research finds pathogenic connection between autoimmune disorders and cancer 2Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 4
... The Drexel University School of Public Health was awarded ... National Institutes of Health for more than $14,300,000 to ... Disorders (ASD) in expectant mothers and their babies. ... network of research sites nationwide to study possible risk ...
... InterMedia, a,Washington, D.C.-based research, evaluation and consulting ... Afghanistan that finds,low awareness and knowledge levels about ... media are important predictors for heightened,awareness., Some ... Afghanistan include:, -- Only 1 percent of ...
... The American College of Physicians (ACP), along with other ... Healthcare Decisions Day. Set for April 16, 2008, the ... United States to talk to their family or doctor ... their healthcare wishes in a living will, and for ...
... This month,Sharing Miracles - a 30-minute public ... stories of real patients - will feature,Joey Pantoliano, ... from mental depression., Pantoliano is one of ... than 100 movies and television shows. But he ...
... BETHESDA, Md. (April 2, 2008) Two Mayo Clinic researchers ... the arteries and in the formation of kidney stones, will ... the bodys physiology. The symposium will take place April 8 ... are a thousand times smaller than the bacteria, E. coli, ...
... Inc. (OTC Bulletin Board: FGHH) today stated that on ... provided a 2008,revenue forecast of approximately $6.2 million. The ... 2008 gross margins of 61 percent., A re-broadcast ... Global Health,s website, http://www.flagshipglobalhealth.com, no later,than April ...
Cached Medicine News:Health News:Drexel School of Public Health awarded $14M NIH grant for autism research 2Health News:Drexel School of Public Health awarded $14M NIH grant for autism research 3Health News:Education and Media Key to Improving HIV/AIDS Awareness and Knowledge Levels in Afghanistan, New InterMedia Report Says 2Health News:Education and Media Key to Improving HIV/AIDS Awareness and Knowledge Levels in Afghanistan, New InterMedia Report Says 3Health News:'Sharing Miracles' Television Program to Feature Emmy Award-Winning Actor Joey Pantoliano 2Health News:'Sharing Miracles' Television Program to Feature Emmy Award-Winning Actor Joey Pantoliano 3Health News:'Sharing Miracles' Television Program to Feature Emmy Award-Winning Actor Joey Pantoliano 4Health News:Symposium to explore role nanoparticles may play in disease 2Health News:Flagship Global Health Provides 2008 Financial Guidance 2
Long handle occluders are approximately 9 inches long....
Long handle occluders are approximately 9 inches long....
Manual Lensmeter....
Lightweight, cordless lensmeter....
Medicine Products: